Source link : https://newshealth.biz/health-news/defining-the-role-of-oral-serds-in-frontline-metastatic-breast-cancer/
At the American Society of Clinical Oncology (ASCO) meeting, results from the phase III persevERA BC trial did not show a statistically significant progression-free survival (PFS) benefit with the investigational oral selective estrogen receptor degrader (SERD) giredestrant plus palbociclib (Ibrance) versus standard endocrine therapy plus palbociclib in first-line hormone receptor-positive, HER2-negative metastatic breast cancer. In […]
The post Defining the Role of Oral SERDs in Frontline Metastatic Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-23 16:15:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8